Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Kelley RK, et al. Among authors: hazra s. Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4. Lancet Oncol. 2022. PMID: 35798016 Free article. Clinical Trial.
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
Kelley RK, Miksad R, Cicin I, Chen Y, Klümpen HJ, Kim S, Lin ZZ, Youkstetter J, Hazra S, Sen S, Cheng AL, El-Khoueiry AB, Meyer T, Abou-Alfa GK. Kelley RK, et al. Among authors: hazra s. Br J Cancer. 2022 Mar;126(4):569-575. doi: 10.1038/s41416-021-01532-5. Epub 2021 Oct 7. Br J Cancer. 2022. PMID: 34621044 Free PMC article. Clinical Trial.
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M. Tao JJ, et al. Among authors: hazra s. Sci Signal. 2014 Mar 25;7(318):ra29. doi: 10.1126/scisignal.2005125. Sci Signal. 2014. PMID: 24667376 Free PMC article.
Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma.
St John MA, Dohadwala M, Luo J, Wang G, Lee G, Shih H, Heinrich E, Krysan K, Walser T, Hazra S, Zhu L, Lai C, Abemayor E, Fishbein M, Elashoff DA, Sharma S, Dubinett SM. St John MA, et al. Among authors: hazra s. Clin Cancer Res. 2009 Oct 1;15(19):6018-27. doi: 10.1158/1078-0432.CCR-09-0011. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789323 Free PMC article.
Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.
Liclican EL, Walser TC, Hazra S, Krysan K, Park SJ, Pagano PC, Gardner BK, Larsen JE, Minna JD, Dubinett SM. Liclican EL, et al. Among authors: hazra s. Cancer Prev Res (Phila). 2014 Aug;7(8):845-55. doi: 10.1158/1940-6207.CAPR-14-0063. Epub 2014 Jun 9. Cancer Prev Res (Phila). 2014. PMID: 24913817 Free PMC article.
427 results